VAUGHAN, Ontario—Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced that it is exploring a potential sale, among other options, in order to complete a separation from parent company Bausch Health. The announcement, shared in a statement yesterday following a request by the Canadian Investment Regulatory Organization (CIRO), elaborates in saying that Bausch + Lomb's board of directors authorized management and its advisors to explore a potential sale as one of several potential options to fully separate from its parent company. The process is ongoing, the statement advised, and there is no assurance that it would result in a transaction.

“While the company normally would not comment on deal negotiations, CIRO requested confirmation of a potential sale process given stock volatility often associated with market rumors," the statement indicated. "Bausch + Lomb does not intend to provide additional detail until further disclosure is appropriate or necessary.”

When contacted by VMAIL, Bausch + Lomb declined further comment.

Bausch Health Companies Inc. (NYSE/TSX:BHC), a global, diversified pharmaceutical company, added the following statement:  "As previously disclosed, the Bausch Health Companies believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation, makes strategic sense.”

Most recent revenue performance for Bausch Health and Bausch + Lomb, reported on October 30, 2024, for the 3 months ending September 30, 2024, showed 12 percent and 19 percent year-over-year growth, respectively. Total consolidated reported revenues for Bausch Health were $2,510 million for the quarter, an increase of $272 million, with Bausch + Lomb reporting revenues of $1,196 million for the quarter, an increase of $189 million. Both Bausch Health and Bausch + Lomb are traded on the New York Stock Exchange and Toronto Stock Exchange.